Mechanisms of pharmacokinetic and pharmacodynamic drug interactions associated with ritonavir-enhanced tipranavir.
about
Drug interactions with new and investigational antiretrovirals.Metabolism-mediated drug interactions associated with ritonavir-boosted tipranavir in mice.Use of antineoplastic agents in patients with cancer who have HIV/AIDS.Targeted therapies to treat non-AIDS-defining cancers in patients with HIV on HAART therapy: treatment considerations and research outlook.Effect of Ritonavir on (99m)Technetium-Mebrofenin Disposition in Humans: A Semi-PBPK Modeling and In Vitro Approach to Predict Transporter-Mediated DDIsInduction effects of ritonavir: implications for drug interactions.Determination of intracellular unbound concentrations and subcellular localization of drugs in rat sandwich-cultured hepatocytes compared with liver tissue.Warfarin-antiretroviral interactions.Lack of effect of efavirenz on the pharmacokinetics of tipranavir-ritonavir in healthy volunteers.Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxoneAntiviral drug disposition and natural health products: risk of therapeutic alteration and resistance.Drug interactions with antiretrovirals and warfarin.An update on ABCB1 pharmacogenetics: insights from a 3D model into the location and evolutionary conservation of residues corresponding to SNPs associated with drug pharmacokinetics.Single nucleotide polymorphisms in clinics: Fantasy or reality for cancer?Neurotoxicity in the Post-HAART Era: Caution for the Antiretroviral Therapeutics.Pharmacokinetic interaction of vicriviroc with other antiretroviral agents: results from a series of fixed-sequence and parallel-group clinical trials.
P2860
Q33801821-8CAD90E0-B75B-4376-8C55-A16465D16CEAQ33861897-FFDAE917-859A-41E4-9008-12ACA0F7B832Q35932561-94A621CD-4351-4923-ADDB-444BFDB0D8C4Q36040272-0EA7EA6A-9C4D-4294-86D3-CC393BB0B7C5Q36693701-605F34A7-F90C-4FAD-B19B-49FDD678908FQ37199533-618EA317-A67B-42F4-986A-1F0F0B61BF12Q37251993-11BA0020-09F1-4822-BEFB-475BB2D535F4Q37386503-60CEAE2C-157A-4BDB-BBC7-C1D54D7D2C3DQ37409968-DD25AA28-4E42-474E-BF8F-991ED33924ECQ37425629-131D1115-04CD-4089-8358-11D2CE05B7D3Q37481442-92DDCD9A-139F-4E42-8E93-83059871ABF6Q37679935-94BDC933-B36D-4B5D-9227-0AAE1828EBD4Q37882401-21249DCE-77CC-45FA-86E8-A893AF12C305Q38591731-E791A6FC-4962-47AE-9B8A-BFEFF2732213Q38882614-BD7CB0A5-880A-4379-96E7-27AA5C2C93A3Q43689055-E891919A-D888-40DC-A5B5-F30AB399BACC
P2860
Mechanisms of pharmacokinetic and pharmacodynamic drug interactions associated with ritonavir-enhanced tipranavir.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Mechanisms of pharmacokinetic ...... ritonavir-enhanced tipranavir.
@ast
Mechanisms of pharmacokinetic ...... ritonavir-enhanced tipranavir.
@en
Mechanisms of pharmacokinetic ...... ritonavir-enhanced tipranavir.
@nl
type
label
Mechanisms of pharmacokinetic ...... ritonavir-enhanced tipranavir.
@ast
Mechanisms of pharmacokinetic ...... ritonavir-enhanced tipranavir.
@en
Mechanisms of pharmacokinetic ...... ritonavir-enhanced tipranavir.
@nl
prefLabel
Mechanisms of pharmacokinetic ...... ritonavir-enhanced tipranavir.
@ast
Mechanisms of pharmacokinetic ...... ritonavir-enhanced tipranavir.
@en
Mechanisms of pharmacokinetic ...... ritonavir-enhanced tipranavir.
@nl
P2860
P356
P1433
P1476
Mechanisms of pharmacokinetic ...... ritonavir-enhanced tipranavir.
@en
P2093
Angela D M Kashuba
Manoli Vourvahis
P2860
P304
P356
10.1592/PHCO.27.6.888
P407
P577
2007-06-01T00:00:00Z